Translating discoveries into medicine: Psychiatric drug development in 2011

Neuropsychopharmacology

Volumn 37, Issue 1, 2012, Pages 281-283

  Brady, Linda S ^a   Insel, Thomas R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; GENERIC DRUG; NEUROLEPTIC AGENT;

AUTISM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA;

ANIMALS; DRUG DESIGN; HUMANS; MENTAL DISORDERS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PSYCHOPHARMACOLOGY; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84856092237     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.106     Document Type: Note

References (10)

1. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S et al (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature 473: 221-225.
2. Cohen AF (2010). Developing drug prototypes: pharmacology replaces safety and tolerability? Nat Rev Drug Discov 9: 856-865.
3. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al (2010). Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167: 748-751.
4. Insel TR (2007). From animal models to model animals. Biol Psychiatry 62: 1337-1339. (Pubitemid 350180731)
5. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y et al (2010). A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143: 527-539.
6. Mullard A (2011). Could pharma open its drug freezers? Nat Rev Drug Discov 10: 399-400.
7. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al (2010). How to improve R&D productivity: the pharmaceutical industry0s grand challenge. Nat Rev Drug Discov 9: 203-214.
8. Strauss S (2011). Open access consortium. Nat Biotechnol 29: 298.
9. Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011). Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 99: 130-145.
10. Woodcock J, Griffin JP, Behrman RE (2011). Development of novel combination therapies. N Engl J Med 364: 985-987.